Cell MedX Corp Share Price OTC Bulletin Board
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
15/04 | Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024 | CI |
12/03 | Cell MedX Corp. announced that it has received $0.075 million in funding | CI |
Sales 2022 | 0.01 0.51 | Sales 2023 | 0 0.23 | Capitalization | 6.29K 525K |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | - 0 | EV / Sales 2022 | 1,13,51,53,669 x |
Net Debt 2022 | 592K 49.39M | Net Debt 2023 | 903K 75.27M | EV / Sales 2023 | 32,91,16,944 x |
P/E ratio 2022 |
-9.01
x | P/E ratio 2023 |
-0.01
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 20.34% |
Managers | Title | Age | Since |
---|---|---|---|
David Jeffs
CEO | Chief Executive Officer | 54 | 12/12 |
Yanika Silina
DFI | Director of Finance/CFO | 45 | 24/14/24 |
George Adams
CHM | Chairman | 76 | 23/18/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Jeffs
CEO | Chief Executive Officer | 54 | 12/12 |
Dwayne Yaretz
BRD | Director/Board Member | 63 | 27/22/27 |
Joao da Costa
BRD | Director/Board Member | 59 | 08/20/08 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |